This is the authors' abstract. We don't add key points for this paper.
In 7 of 18 solid-organ transplant recipients with primary human cytomegalovirus (HCMV) infection, HCMV antigenemia levels were unexpectedly found to rise significantly (P = 0.018) during a mean time of 7.3 +/- 3.2 days after initiation of specific antiviral treatment, whereas corresponding levels of viremia dropped significantly (P = 0.043). Thus, shifting to an alternative antiviral drug based solely on increasing antigenemia levels is not justified in this group of patients.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Gerna et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: